Dept. of Medicine, Div. of Endocrinology, Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands; Leiden Metabolic Research Services, Leiden University Medical Center, Leiden, The Netherlands.
Division of Clinical Pharmacology, Vanderbilt University, Nashville, TN 37232-6602, USA.
Atherosclerosis. 2017 Sep;264:100-107. doi: 10.1016/j.atherosclerosis.2017.06.916. Epub 2017 Jun 21.
Oxidative modification of lipoproteins is a crucial step in atherosclerosis development. Isotopic-reinforced polyunsaturated fatty acids (D-PUFAs) are more resistant to reactive oxygen species-initiated chain reaction of lipid peroxidation than regular hydrogenated (H-)PUFAs. We aimed at investigating the effect of D-PUFA treatment on lipid peroxidation, hypercholesterolemia and atherosclerosis development.
Transgenic APOE*3-Leiden.CETP mice, a well-established model for human-like lipoprotein metabolism, were pre-treated with D-PUFAs or control H-PUFAs-containing diet (1.2%, w/w) for 4 weeks. Thereafter, mice were fed a Western-type diet (containing 0.15% cholesterol, w/w) for another 12 weeks, while continuing the D-/H-PUFA treatment.
D-PUFA treatment markedly decreased hepatic and plasma F-isoprostanes (approx. -80%) and prostaglandin Fα (approx. -40%) as compared to H-PUFA treatment. Moreover, D-PUFAs reduced body weight gain during the study (-54%) by decreasing body fat mass gain (-87%) without altering lean mass. D-PUFAs consistently reduced plasma total cholesterol levels (approx. -25%), as reflected in reduced plasma non-HDL-cholesterol (-28%). Additional analyses of hepatic cholesterol metabolism indicated that D-PUFAs reduced the hepatic cholesterol content (-21%). Sterol markers of intestinal cholesterol absorption and cholesterol breakdown were decreased. Markers of cholesterol synthesis were increased. Finally, D-PUFAs reduced atherosclerotic lesion area formation throughout the aortic root of the heart (-26%).
D-PUFAs reduce body weight gain, improve cholesterol handling and reduce atherosclerosis development by reducing lipid peroxidation and plasma cholesterol levels. D-PUFAs, therefore, represent a promising new strategy to broadly reduce rates of lipid peroxidation, and combat hypercholesterolemia and cardiovascular diseases.
脂蛋白的氧化修饰是动脉粥样硬化发展的关键步骤。与常规氢化(H-)多不饱和脂肪酸(PUFAs)相比,同位素增强的多不饱和脂肪酸(D-PUFAs)更能抵抗活性氧引发的脂质过氧化链式反应。我们旨在研究 D-PUFA 处理对脂质过氧化、高胆固醇血症和动脉粥样硬化发展的影响。
载脂蛋白 E*3-Leiden.CETP 转基因小鼠是一种建立良好的类似于人类脂蛋白代谢的模型,用 D-PUFA 或对照 H-PUFA 饮食(1.2%,w/w)预处理 4 周。此后,继续 D-/H-PUFA 处理,让小鼠再喂食 12 周的西方型饮食(含有 0.15%胆固醇,w/w)。
与 H-PUFA 处理相比,D-PUFA 处理显著降低了肝和血浆 F-异前列腺素(约 -80%)和前列腺素 Fα(约 -40%)。此外,D-PUFAs 通过减少体脂质量增加(-87%)而不改变瘦体重,从而减少了研究期间的体重增加(-54%)。D-PUFAs 一致降低了血浆总胆固醇水平(约 -25%),反映在降低了非高密度脂蛋白胆固醇(-28%)。对肝胆固醇代谢的进一步分析表明,D-PUFAs 降低了肝胆固醇含量(-21%)。肠道胆固醇吸收和胆固醇分解的固醇标志物减少。胆固醇合成标志物增加。最后,D-PUFAs 减少了整个心脏主动脉根部的动脉粥样硬化病变面积形成(-26%)。
D-PUFAs 通过降低脂质过氧化和血浆胆固醇水平,减少体重增加,改善胆固醇处理并减少动脉粥样硬化发展。因此,D-PUFAs 代表了一种有前途的新策略,可以广泛降低脂质过氧化率,对抗高胆固醇血症和心血管疾病。